CytomX Therapeutics CTMX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's total current liabilities?
- CytomX Therapeutics (CTMX) reported total current liabilities of $34.02M in Q1 2026.
- How has CytomX Therapeutics's total current liabilities changed year-over-year?
- CytomX Therapeutics's total current liabilities decreased by 32.2% year-over-year, from $50.2M to $34.02M.
- What is the long-term trend for CytomX Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), CytomX Therapeutics's total current liabilities has grown at a -7.3% compound annual growth rate (CAGR), from $68.11M to $46.62M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.